Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care
July 29, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances.LumiraDx’s transformative Point of Care solution will complement Roche’s diagnostics...
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Halbjahr 2024 um 5% (CER); starkes Wachstum im zweiten Quartal – Gewinnprognose für das Gesamtjahr erhöht
July 25, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Konzernverkäufe stiegen im ersten Halbjahr um 5%1 zu konstanten Wechselkursen (CER; stabil in CHF) dank starker Nachfrage sowohl nach Medikamenten als auch nach Diagnostika; ohne COVID-19-Produkte...
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised
July 25, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Group sales were up by 5%1 at constant exchange rates (CER) (stable in CHF) in the first half, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products,...
New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
July 18, 2024 07:20 ET
|
F. Hoffmann-La Roche Ltd
Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR)Safety data were...
Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study
July 17, 2024 11:45 ET
|
F. Hoffmann-La Roche Ltd
More than 90% of patients had absence of DME after four years in a pre-specified exploratory endpointPeople treated with Vabysmo sustained vision gains and anatomical improvements, with almost 80%...
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity
July 17, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; p < 0.001)1 Pharmacokinetic data supports a once-daily oral dosing...
Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes
July 09, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
The Accu-Chek® SmartGuide CGM solution provides 14 days of accurate1 real-time glucose values for adults living with type 1 and type 2 diabetes on flexible insulin therapy.The built-in AI-trained...
Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)
July 08, 2024 11:45 ET
|
F. Hoffmann-La Roche Ltd
The FDA has approved updates to Susvimo, which will be available to US retina specialists and patients with nAMD in the coming weeksSusvimo offers the first alternative to regular eye injections that...
FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss
July 05, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindnessDesigned to simplify administration, Vabysmo PFS...
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer
July 04, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free survival at primary analysis and overall survival at first interim...